Renal Disease


The prevalence of renal complications among patients with HIV infection has increased as more patients with HIV are living longer as a result of effective antiretroviral therapy (ART) and opportunistic infection prophylaxis. More widespread access to and earlier initiation of ART has decreased the incidence of HIV-associated nephropathy (HIVAN), but other causes of renal disease persist, and in some cases are increasing in prevalence. These may be infections and other conditions related to HIV infection, other comorbidities (e.g., hypertension, diabetes), or medication adverse effects, including those caused by some antiretroviral (ARV) medications (see "Kidney disease associated with HIV infection" and Table 2, below).

Risk factors for renal disease in HIV-infected patients include the following:

  • CD4 count <200 cells/µL
  • HIV viremia, particularly RNA levels >4,000 copies/mL
  • African-American race
  • Family history of kidney disease
  • Use of nephrotoxins (including medications; see Table 2, below)
  • Comorbidities
  • Diabetes mellitus
  • Hypertension
  • Hepatitis C

Renal disease in HIV-infected individuals can occur as a primary disease, as a secondary disease in the setting of other systemic illness, or as an adverse effect of medications. In the United States, the most common causes of end-stage renal disease in the general population are diabetes mellitus and hypertension. HIV-infected patients are at a fourfold higher risk of developing diabetes mellitus and a threefold higher risk of developing hypertension compared with seronegative individuals. Chronic hepatitis C, seen in 30-40% of HIV-infected individuals in the United States, is associated with several types of chronic kidney disease, including progressive secondary glomerulonephropathy, membranoproliferative glomerulonephropathy, and mixed cryoglobulinemia.

Note that ART should be given to HIV-infected individuals with renal disease, according to usual criteria for ART initiation; however, some ARVs must be avoided and some should be given at modified dosages according to the degree of renal dysfunction (see Table 3). Additionally, for patients with HIVAN, ART is the primary treatment.


Screening for kidney disease in HIV-infected persons is an important aspect of primary care, as patients typically have no symptoms until very late. High-risk patients (see list of risk factors, above) should be identified and monitored. Early identification of patients with renal dysfunction allows early intervention targeted at reversing the process of renal injury or slowing its progression. Current guidelines of the U.S. Department of Health and Human Services (HHS) and the Infectious Diseases Society of America recommend screening at entry to care, with subsequent screening as indicated by the patient's risk factors.

Screening consists of three tests:

Figure 1. Follow-Up for Patients with Normal Screening Test Results

Exposure Risk Algorithm

Figure 1. Follow-Up for Patients with Normal Screening Test Results

Exposure Risk Algorithm
  • Serum creatinine (Cr) and calculated estimate of renal function (eGFR); The eGFR usually is provided by the laboratory but may be calculated as follows:
    • eGFR by the Modification of Diet in Renal Disease (MDRD) equation:

      GFR (mL/min/1.73 m2) = 186 x [serum Cr (mg/dL)]-1.154 x [age (years)]-0.203 x [0.742 if female] x [1.212 if African-American]

      • Normal GFR: ≥90 mL/min/1.73 m2
      • Chronic kidney disease (CKD): GFR <60 mL/min/1.73 m2

      An online eGFR calculator is available.

    • The creatinine clearance (CrCl) can be used as a surrogate for eGFR but is considered to be less accurate. Note that CrCl is used in determining medication dosages.
      • CrCl (Cockroft-Gault equation):

        (140 - age) x (weight in kilograms); multiply by 0.85 for females
        72 x serum Cr (mg/dL)

  • Urinalysis, for proteinuria, hematuria
  • Quantitative test for proteinuria (if eGFR <60 mL/min/1.73m2or ≥1+ protein on dipstick):
    • Random urinary protein to urinary Cr ratio (U Pr/U Cr)
    • This estimates 24-hour protein excretion and correlates well with grams per day of proteinuria; for example, a random U Pr/U Cr of 1.0 correlates with 1 g/day of proteinuria (normal is ≤0.2)

    Suggested follow-up for patients with normal screening test results is shown in Figure 1; suggested follow-up of abnormal screening test results is shown in "Diagnostic Evaluation."

S: Subjective

As noted above, patients usually have no symptoms until late in the course of kidney disease and are diagnosed on the basis of laboratory abnormalities.

In symptomatic patients, presenting signs or symptoms are nonspecific. Patients with renal failure may present with fatigue, weakness, anorexia, nausea, pruritus, vomiting, edema, diminished urine output, discolored urine, altered mental status, and seizures. Those with renal disease associated with systemic illnesses may present with fever, arthralgias, respiratory symptoms, flank pain, abdominal pain, and diarrhea.

For patients with renal disease suspected on the basis of laboratory abnormalities (e.g., elevated serum Cr [azotemia], electrolyte disturbances, acid-base disorders, proteinuria, hematuria, and anemia), and for symptomatic patients with known kidney disease, ask about the risk factors and symptoms described above, and about the following:

  • Systemic illness
    • Night sweats, fever, weight loss
    • Shortness of breath, cough, hemoptysis, nasal congestion, rhinorrhea
    • Diarrhea, hematochezia, melena
    • Dysuria, frequency, urgency, polyuria, decreased urine output, discoloration of urine
    • Skin rash or skin lesions
    • Edema, arthralgias, painful swollen joints, myalgias
  • Family history of kidney disease, hyper-tension, diabetes mellitus
  • Recent radiographic imaging with IV contrasts (including those containing gadolinium or iodinated agents)

Review the patient's medication list (see Table 1).

  • Include over-the-counter medications, nonsteroidal antiinflammatory drugs, phosphate-containing enemas

O: Objective

Check blood pressure, temperature, and weight. Compare these with values from previous readings. Perform a physical examination, including evaluations of the following:

  • Volume status (blood pressure, pulse, skin turgor, mucous membrane moistness, edema)
  • Optic fundi (signs of retinopathy)
  • Cardiovascular system (peripheral pulses, bruits), to assess for peripheral vascular disease
  • Abdomen (auscultate for unilateral bruit [renal artery stenosis], distention, mass, organomegaly, tenderness)
  • Musculoskeletal system (bruises, muscle pain, muscle weakness, swollen joints)
  • Skin (rash to help evaluate for drug reaction, vasculitis)
  • Rectum (enlarged prostate, if obstruction is suspected)

Review previous laboratory values (e.g., serum Cr, blood urea nitrogen [BUN], electrolytes, urinalysis) to determine whether the kidney disease is acute or chronic.

  • Acute kidney injury (AKI) is assumed if there are no previous serum Cr values.

The presence of an abnormal GFR (≤60 mL/min for at least 3 months) suggests chronic kidney disease (CKD).

Review the CD4 cell count and HIV viral load.

A: Assessment

Once the duration of the elevated serum Cr is assessed, a differential diagnosis can be made.

The causes of renal failure are classified traditionally based on the area of the renal anatomy where the injury occurred: prerenal, renal, and postrenal (obstructive uropathy). Acute tubular necrosis (ATN) is the most common cause of acute kidney injury.

Table 1. Causes of Renal Failure
Prerenal Renal Postrenal
Abbreviations: ACE = angiotensin-converting enzyme; HUS = hemolytic uremic syndrome; NSAID = nonsteroidal antiinflammatory drug; TTP = thrombotic thrombocytopenic purpura
Laboratory Data
  • Urine sodium (Na) <30 mEq/L
  • Fractional excretion of Na (FeNa) <1% (see below)
  • Fractional excretion of urea <35%
  • Serum BUN: serum Cr ratio ≥20
  • Urine Na >30 mEq/L
  • FeNa >1% (see below)
  • Fractional excretion of urea >50
  • Serum BUN: serum Cr ratio ≥10


Imaging showing obstruction

Partial Differential Diagnosis

Decreased renal perfusion

  • Volume depletion
  • Effective volume depletion
    • Heart failure
    • Cirrhosis
    • Shock

Vascular disease

  • Renal artery stenosis

Medication induced

  • Prostaglandin inhibition (NSAID)
  • ACE inhibitors and angiotensin receptor blockers

Acute Tubular Necrosis

Ischemia leading to ATN

  • Prolonged hypotension attributable to any cause
    • Sepsis syndrome
    • Volume depletion (gastrointestinal bleeding)
  • Atheroembolism and thromboembolism
  • Systemic vasculitis
  • Thrombotic microangiopathy (TTP, HUS)

Endogenous toxins

  • Myoglobin (rhabdomyolysis)
  • Uric acid and calcium-phosphate complexes (tumor lysis syndrome)

Exogenous-induced ATN

  • Aminoglycosides
  • Amphotericin B
  • Foscarnet
  • Ganciclovir
  • Intravenous pentamidine
  • Tenofovir
  • Chemotherapeutic agents (methotrexate, cisplatinum)


  • Many specific types; some associated with HIV (including HIVAN) or associated infections and other conditions

Other intrarenal lesions

  • Acute interstitial nephritis (AIN)
  • Drug induced
  • Infections associated with AIN
    • Bacterial (Streptococcus, Mycobacteria, Legionella, Pneumococcus)
    • Viral (Epstein-Barr, herpes simplex type 1, cytomegalovirus, BK virus)
    • Fungal (histoplasmosis, candidiasis)
    • Other infections (toxoplasmosis, syphilis, schistosomiasis, malaria, leptospirosis)
  • Infectious
    • Granulomatous (mycobacterial disease, coccidioidomycosis, histoplasmosis)
  • Tumors
    • Multiple myeloma
    • Lymphoma
  • Nephrolithiasis
    • Intratubular obstruction
      • Drug-induced crystalluria
        • Antiviral (acyclovir, indinavir, atazanavir)
        • Antibiotic (trimethoprim/sulfamethoxazole)

Prostate hypertrophy


Stones or crystal deposition

Kidney Disease Associated with HIV Infection

A discussion of glomerulonephropathy is beyond the scope of this chapter, but HIV and associated comorbidities (e.g., infections such as hepatitis C, hepatitis B, and cytomegalovirus, along with malignancies, heroin use, nephrotoxic medications, diabetes mellitus, and hypertension) are among the many causes of glomerulonephropathy. The condition most closely associated with HIV is HIVAN. This is a collapsing focal segmental glomerulosclerosis (FSGS) that usually occurs in persons of African heritage, and particularly those with a low CD4 count or high HIV RNA level. The clinical presentation includes the following:

  • Nephrotic syndrome or nonnephrotic proteinuria
  • Normal blood pressure
  • Elevated Cr, often with rapid progression to end-stage renal disease (<6 months)
  • Renal ultrasound usually reveals normal size or slightly enlarged echogenic kidneys
  • Renal biopsy shows a collapsing FSGS

In addition, several conditions may be caused by ARV medications. Tenofovir may cause, though rarely, AKI with type 2 renal tubular acidosis (RTA) and Fanconi syndrome. Alternatively, it more commonly causes a gradual increase in serum Cr over a period of months or years; this appears to occur more frequently in persons concomitantly taking ritonavir-boosted PIs and perhaps also in those taking cobicistat. Patients who take tenofovir should have renal function monitored every 3-6 months. Indinavir can cause crystalluria, nephrolithiasis, and acute interstitial nephritis, and atazanavir can cause nephrolithiasis.

Some other medications commonly used in the treatment of patients with HIV infection and associated conditions may cause acute or chronic kidney injury. See Table 1, above, and Table 2, below.

It should be noted that several ARVs (including the NNRTI rilpivirine and the integrase inhibitor dolutegravir) as well as the pharmacokinetic inhibitor cobicistat (in the coformulation elvitegravir/cobicistat/tenofovir/emtricitabine, Stribild) may inhibit renal tubular secretion of creatinine and thus cause modest increases in serum Cr (in the range of 0.1-0.2 mg/dL) and modest decreases in eGFR. This does not result from kidney injury, and actual GFR remains stable. These creatinine increases occur in the initial weeks of treatment with one of these agents and remain stable afterward (if increases in Cr exceed what is expected for these drugs, it is important to conduct an evaluation for other causes).

Table 2. Selective Drugs Causing Acute or Chronic Kidney Injury in HIV-Infected Patients
Drugs Acute Tubular Necrosis Acute Interstitial Nephritis Other Associated Abnormalities
Antiretroviral Medications
Abacavir   +/-  
Atazanavir   + Nephrolithiasis
Indinavir   + Crystalluria
Tenofovir +  

Fanconi syndrome (hypokalemia, non-gap metabolic acidosis, hypophosphatemia, glycosuria)

May cause a slow increase in Cr

Other Medications
TMP-SMX (Bactrim, Septra)   +++ Hyperkalemia, crystalluria
Beta-lactams   ++  
Sulfonamides   ++  
Fluoroquinolones   +  
Aminoglycosides (e.g., streptomycin, gentamycin, amikacin) +++    
Rifampin + +  
Isoniazid   + Overdose leads to high anion gap metabolic acidosis
Dapsone +/-   Papillary necrosis
Amphotericin B +++   Hypokalemia, hypernatremia (nephrogenic diabetes insipidus)
Pentamidine +++   Crystalluria
Foscarnet +++    
Ganciclovir +    
Acyclovir +   Crystalluria
NSAIDs   + Proteinuria, secondary minimal change disease, papillary necrosis

P: Plan

Diagnostic Evaluation

Figure 2. Workup of Abnormal Screening Test Results

Workup of Abnormal Screening Test Results

Figure 2. Workup of Abnormal Screening Test Results

Workup of Abnormal Screening Test Results

Determine whether the renal disease is acute or chronic, as above (see "O: Objective").

Perform a targeted laboratory evaluation, depending on results of initial tests, history, and physical examination.

  • Urinalysis with microscopy and examination of urine sediment (e.g., hematuria, pyuria, casts) can help in identifying etiologies such as nephritic syndrome, ATN, or infection.
  • Quantify the proteinuria by obtaining a random urine protein-to-urine creatinine ratio (U Pr/U Cr), if not done already; this correlates well with grams per day of proteinuria, as discussed above.
  • Fractional excretion of sodium (FeNa) may be helpful in distinguishing causes of acute kidney injury.
    • FeNa =

      Urine sodium ÷ Serum sodium
      Urine Cr ÷ Serum Cr

    • FeNa <1 is highly suggestive of prerenal state
    • FeNa >1 is suggestive of intrinsic renal injury
  • Urine culture, if urinary tract infection is suspected

Further workup will depend on the findings and the suspected cause.


Proteinuria can be present in patients with primary renal disease, and also in those with hypertension, diabetes mellitus, vascular disease, collagen vascular disease, malignancy, or certain infections. Proteinuria is not always pathologic and may be caused by transient conditions such as pregnancy, strenuous exercise, fever, seizure, or congestive heart failure; in some cases, it may be benign. However, proteinuria should be evaluated if it persists. If present with hematuria, proteinuria is highly suspicious for a glomerular disease.

The major classifications of persons with proteinuria are as follows:

Nephrotic syndrome:

  • >3.5 g/day proteinuria
  • "Bland" sediment, with no or few red or white blood cells
  • Edema
  • Hyperlipidemia
  • Hypoalbuminemia
  • Check serum complements (C3 and C4):
    • Low complements: glomerulonephritis associated with subacute bacterial endocarditis, infection (postinfectious), lupus, membranoproliferative glomerulonephritis, and mixed cryoglobulinemia


  • Proteinuria
  • "Active" sediment, with white and red blood cells; may see red blood cell casts
  • Further categorized into those with normal renal function and those with abnormal renal function


For asymptomatic isolated microscopic hematuria, obtain a follow-up urinalysis. If hematuria is persistent, obtain a renal and bladder ultrasound. If the result is normal, the eGFR is normal, and there are no other urine abnormalities, conduct routine follow-up with urinalysis and serum Cr testing. Refer patients aged ≥40 with persistent hematuria to a urologist for formal evaluation. Consider checking urine cytology, though that test is not sensitive enough to rule out genitourinary malignancy.

Red blood cell casts

Red blood cell casts strongly suggest glomerulonephritis, which can progress rapidly.


ATN is the most common cause of AKI. A history of certain medication exposures, recent IV contrast, and concurrent illness may provide important clues to ATN. Laboratory findings that are consistent with ATN include increasing serum Cr and a characteristic urine sediment that shows "muddy brown" casts, which are casts that contain densely packed tubular cells.


During AIN, the classic triad of AKI, fever, and rash is not always present. Laboratory findings suggestive of AIN in the setting of AKI include sterile pyuria and eosinophiluria.

Sterile pyuria

Sterile pyuria also may occur in malignancy (e.g., renal, bladder), and in genitourinary tuberculosis. If tuberculosis is suspected, further testing usually requires three first-void urine specimens sent for acid-fast bacilli culture.

Crystalluria and nephrolithiasis

Usual causes of nephrolithiasis should be considered in patients with hematuria, particularly if symptoms consistent with nephrolithiasis are present. Other causes in persons with HIV infection include some medications, including the ARVs indinavir and (rarely) atazanavir; see Table 2 above.

Obtain radiographic imaging (see below) as part of the initial evaluation, and send the passed renal stone, if available, for analysis in order to provide more specific recommendations for management. If there is suspicion that the condition is caused by a medication, order specific chemical analysis (e.g., for atazanavir).

In patients with multiple renal stones, active renal stone formation, and recurrent kidney stones, a metabolic evaluation should be done. This includes a serum intact parathyroid hormone measurement and 24-hour urine collection for Cr, sodium, calcium, oxalate, uric acid, and citrate.


Radiographic imaging of the kidneys is important in the evaluation of renal disease. The size and echogenicity of the kidneys may help differentiate acute and chronic kidney disease. Small and echogenic kidneys are consistent with CKD, though HIV, diabetes, and some other chronic conditions are associated with normal size or large kidneys. Imaging also helps identify obstruction (though the absence of hydronephrosis does not completely rule that out), malignancy, and other conditions.

Both spiral computed tomography (CT) scan and renal ultrasound are acceptable radiographic imaging studies for nephrolithiasis. The advantage of spiral CT scan is its ability to localize stones and assess their size without the use of contrast. Gallium renal scan may be helpful in AIN.

Renal biopsy

Biopsy is not always indicated for patients with renal disease, but it can be very helpful in establishing some diagnoses and determining treatment options.


Patients with proteinuria will benefit from angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Follow the serum potassium and Cr during treatment with an ACEI or ARB (check 1 week after initiation, then periodically). Follow the JNC VII (Joint National Committee on Prevention, Detection, Evaluation and Treatment of Blood Pressure) guidelines for blood pressure control. For patients with hypertension and proteinuria, the target blood pressure is <125/80 mm Hg.

The cornerstone of HIVAN management is fully suppressive ART, and this should be quickly initiated or optimized in all patients, if possible. An ACEI or ARB also should be used to treat proteinuria. A trial of corticosteroids can be considered for patients with deteriorating kidney function while on effective ART plus an ACEI or ARB; consult with a specialist.

For ATN and AIN, discontinue the offending medications and provide supportive care, which may include gentle volume repletion, replacement of bicarbonate deficit, and management of electrolyte abnormalities (e.g., hyperkalemia); consult with a renal specialist.

Other modalities of treatment such as steroids or immunomodulators may be needed, depending on the specific glomerular disease diagnosed by renal biopsy.

Uncomplicated nephrolithiasis can be managed with hydration and pain control. Oral fluid intake should be titrated to produce ≥2 liters of urine output per day. Recommendations for dietary modifications should be based on the 24-hour urine metabolic evaluation. A low-calcium diet usually is not helpful for patients with normal serum calcium and may be detrimental to patients with oxalate renal stones. If the crystalluria is caused by medications, discontinue the offending medications, if possible (in the case of ARVs, make substitutions to maintain optimal virologic suppression).

Patients with complicated nephrolithiasis or pyelonephritis require urgent urologic evaluation.


  • Acute kidney injury
    • Monitor serum electrolytes, BUN and Cr
    • After these normalize, perform routine follow-up
  • Acute interstitial nephritis
    • Avoid offending medications
  • Chronic kidney disease
    • Follow blood pressure closely
      • If hypertensive, consider an ACEI or ARB as first-line medication, as above
      • Target blood pressure is <130/80 mm Hg
      • If evidence of nephropathy, target blood pressure is <125/75 mm Hg
  • For patients with diabetes, optimize blood glucose control
  • Address other risk factors for cardio-vascular disease (see chapter Coronary Heart Disease Risk )
    • Dyslipidemia
    • Cigarette smoking
    • Obesity
    • Physical inactivity
  • Monitor serum electrolytes, BUN, Cr, and hemoglobin
  • Risk of secondary hyperparathyroidism:
  • Serum calcium <9.5 mg/dL
  • Parathyroid hormone level >35 pg/mL
  • Management:
    • Low-phosphate diet
    • Phosphate binders with meals
    • Vitamin D supplement
  • Anemia
    • Consider recombinant human erythropoietin and iron supplement (consult with a nephrologist)
    • Target hemoglobin 11-12 g/dL
  • Avoid nephrotoxins, if possible
  • Adjust medication dosages based on renal function (eGFR); see below

Patients with severe or chronic renal disease should be referred to Nephrology for further evaluation and assistance with the following:

  • Management
  • Education
  • Evaluation for renal replacement therapy
    • Peritoneal dialysis
    • Hemodialysis
  • Kidney transplant evaluation

Medication Dosage Adjustment

Dosages of many medications, including most nucleoside analogues (NRTIs), must be adjusted for patients with CKD, and for those on hemodialysis; see Table 3, below.

Table 3. Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis
Drug Standard Dosage Dosing in Chronic Kidney Disease and Hemodialysis
Abacavir 300 mg PO BID Dosage adjustment for CKD does not appear necessary
Didanosine (enteric-coated capsules) 250 mg to 400 mg PO QD, depending on weight CrCl (mL/min) Weight ≥60 kg Weight <60 kg
≥60 400 mg QD 250 mg QD
30-59 200 mg QD 125 mg QD
10-29 125 mg QD 125 mg QD
<10 125 mg QD Formulation not suitable
HD 125 mg QD Formulation not suitable
Emtricitabine 200 mg PO QD CrCl (mL/min) Dosage
≥50 200 mg QD
30-49 200 mg Q48H
15-29 200 mg Q72H
<15 200 mg Q96H
HD 200 mg Q96H, take after dialysis
Lamivudine 150 mg PO BID or 300 mg PO QD CrCl (mL/min) Dosage
≥50 150 mg BID or 300 mg QD
30-49 150 mg QD
15-29 150 mg first dose, then 100 mg QD
5-14 150 mg first dose, then 50 mg QD
<5 50 mg first dose, then 25 mg QD
HD 50 mg first dose, then 25 mg QD, take after dialysis
Stavudine 20 mg to 40 mg PO BID, depending on weight CrCl (mL/min) Weight ≥60 kg Weight <60 kg
>50 40 mg BID 30 mg BID
26-50 20 mg BID 15 mg BID
10-25 20 mg QD 15 mg QD
HD 20 mg QD, take after dialysis 15 mg QD, take after dialysis
Tenofovir 300 mg PO QD Experience in patients with CrCl <60 mL/min is limited.
CrCl (mL/min) Dosage
≥50 300 mg QD
30-49 300 mg Q48H
10-29 300 mg BIW (i.e., Q 3-4 days)
<10 Not recommended
HD 300 mg once weekly, after dialysis
Zidovudine 300 mg PO BID CrCl (mL/min) Dosage
<15 100 mg TID (or 300 mg QD)
HD 100 mg TID (or 300 mg QD); take after dialysis
Fixed-Dose Combinations
Drug Standard Dosage Dosing in Chronic Kidney Disease and Hemodialysis

Abbreviations: CrCl = creatinine clearance; HD = hemodialysis

Adapted from McNicholl I, Rodriguez R. Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis . In: HIV InSite, Coffey S, Volberding P, eds. San Francisco: UCSF Center for HIV Information. Accessed December 1, 2013.

Atripla (efavirenz/tenofovir/emtricitabine) 1 tab PO QHS Substitute component drugs, adjusting dosage of each drug for CrCl
Combivir (zidovudine/lamivudine) 1 tab PO BID Substitute component drugs, adjusting dosage of each drug for CrCl
Complera (rilpivirine/tenofovir/emtricitabine) 1 tab PO QD Substitute component drugs, adjusting dosage of each drug for CrCl
Epzicom or Kivexa (abacavir/lamivudine) 1 tab PO QD Substitute component drugs, adjusting dosage of each drug for CrCl
Trizivir (zidovudine/abacavir/lamivudine) 1 tab PO BID Substitute component drugs, adjusting dosage of each drug for CrCl
Stribild (elvitegravir/cobicistat/ tenofovir/emtricitabine) 1 tab PO QD Do not initiate if CrCl <70 mg/mL; discontinue if CrCl <50 mg/mL
Truvada (emtricitabine/tenofovir) 1 tab PO QD CrCl (mL/min)
≥50 1 tablet QD
30-49 1 tablet Q48H
<30 Substitute component drugs, adjusting dosage of each drug for CrCl

Protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) do not appear to require dosage adjustment in persons with CKD. Some PIs and NNRTIs, however, do require changes in dosing strategy for patients on hemodialysis. (It should be noted that most PIs have not been studied in the setting of hemodialysis.) The CCR5 antagonist maraviroc should not be used for certain patients with CKD. Available recommendations for hemodialysis patients include the following:


  • Unboosted atazanavir should not be used.
  • Treatment-naive patients: atazanavir must be boosted by ritonavir.
  • Treatment-experienced patients: atazanavir (boosted or unboosted) is not recommended.


  • QD dosing should not be used.
  • In patients with PI resistance, lopinavir/ritonavir levels may be subtherapeutic.


  • CrCl <30 mL/min or on HD: not recommended with potent CYP3A inhibitors or inducers. Without potent CYP3A inhibitors or inducers: 300 mg BID (150 mg BID if postural hypotension occurs).


  • An additional dose (200 mg) should be given after each dialysis session.

Patient Education

  • Early diagnosis of kidney disease is important. Acute kidney injury usually is reversible but may take time and may require temporary hemodialysis support.
  • Advise patients to report all the medications they take, including over-the-counter medications and herbs or supplements.
  • Risk factors for kidney disease are uncontrolled HIV infection (viral load above 4,000 copies/mL and CD4 count <200 cells/µL), coexisting conditions (diabetes mellitus, hypertension, hepatitis C), and ethnicity (African-Americans, Hispanic Americans, Asians, Pacific Islanders, and American Indians). Advise patients that it is important to reduce any modifiable risks, including optimizing HIV control and diabetes mellitus or hypertension management.
  • Advise patients that control of blood pressure is important in slowing the progression of renal disease. Hypertension control can be maximized by both lifestyle modifications (e.g., weight lost, exercise, avoiding excessive alcohol intake) and antihypertensive medications. ACEIs or ARBs are the drugs of choice for patients with hypertension and kidney disease. Target blood pressure is <125/75 mm Hg for patients with proteinuric kidney disease.
  • Educate patients that management of chronic kidney disease helps avoid or control complications such as high blood pressure, weak bones (osteodystrophy), anemia, and nerve damage (neuropathy).
  • When the kidney disease progresses to end-stage renal disease, several options can be explored. These are dialysis, kidney transplant, or palliative care. There are two modes of dialysis, hemodialysis and peritoneal dialysis. A nephrologist and the patient can decide which option is best. HIV control (suppressed viral load, optimal CD4) is required if kidney transplant is to be considered.


  • Aberg JA, Gallant JE, Ghanem KG et al.; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):e1-e34.
  • Atta MG, Gallant JE, Rahman H, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006 Oct;21(10):2809-13.
  • Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol. 2008;28(3):478-86.
  • Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005 Sep 2;19(13):1375-83.
  • Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009 Jul;10(6):329-36.
  • Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005 Jun 1;40(11):1559-85.
  • McNicholl I, Rodriguez R. Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis . In: HIV InSite, Coffey S, Volberding P, eds. San Francisco: UCSF Center for HIV Information. Accessed December 1, 2013.
  • Mocroft A, Kirk O, Reiss P, et al.; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010 Jul 17;24(11):1667-78.
  • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents . Department of Health and Human Services. Accessed December 1, 2013.
  • Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis. 2008 Apr 15;46(8):1282-9.
  • Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004 Sep;66(3):1145-52.
  • Verdecchia P, Staessen J, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomized trial. Lancet. 2009 Aug 15;374(9689):525-33.
  • U.S. Department of Veterans Affairs. Renal Disease . In: Ross D, Coffey S, eds. Primary Care of Veterans with HIV. Washington: U.S. Department of Veterans Affairs, Veterans Health Administration; April 2009;211-25.
  • Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol. 2009 Apr;5(4):193-202.